Abstract
Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix(®)) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
